JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
Cancer
PUBLISHED: 08-25-2014
Show Abstract
Hide Abstract
The validity of the KRAS mutation as a predictor of recurrence-free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection.
Related JoVE Video
c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.
Anticancer Res.
PUBLISHED: 07-31-2013
Show Abstract
Hide Abstract
Data on the clinicopathological features and prognostic impact of c-N-Methyl-N-nitro-N-nitroso-guanidine HOS Transforming gene (c-MET) and hepatocyte growth factor (HGF) in hepatocellular carcinoma (HCC) are inconsistent. We assessed c-MET and HGF expression in 49 patients with early-stage HCC and correlated the results with disease characteristics and survival.
Related JoVE Video
A case report of a patient with advanced acinar cell carcinoma of the pancreas: long-term survival with regional, systemic and targeted therapy.
Tumori
PUBLISHED: 06-11-2013
Show Abstract
Hide Abstract
Acinar cell carcinoma of the pancreas is an uncommon malignancy for which there are no prospective, randomized data to guide therapy. We describe the clinical course and management of a patient with advanced pancreatic acinar cell carcinoma who is alive seven years after diagnosis using systemic and regional chemotherapies as well as molecularly targeted agents.
Related JoVE Video
Targeted agents and systemic therapy in hepatocellular carcinoma.
Recent Results Cancer Res.
PUBLISHED: 01-31-2013
Show Abstract
Hide Abstract
Cytotoxic chemotherapy, hormonal agents, and immunotherapy have been tested in hepatocellular cancer (HCC) with marginal efficacy to date. Recent insights into the molecular pathogenesis of HCC have identified several aberrant signaling pathways that have served as targets for novel therapeutic agents. These discoveries have been translated into the clinical realm with the use of the antiangiogenic and the Raf kinase inhibitor, sorafenib, and have revealed the potential of targeted agents to produce clinically meaningful survival benefits in patients with advanced HCC. Efforts continue in the quest to improve the outcome of HCC patients through the development and evaluation of other targeted agents, and to better understand the interactions between the underlying disease biology and response to therapy. Several pathways are now implicated in hepatocarcinogenesis and agents that target these pathways continue to be developed.
Related JoVE Video
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.
Gastrointest Cancer Res
PUBLISHED: 01-10-2013
Show Abstract
Hide Abstract
Fibrolamellar carcinoma is a rare and poorly understood malignancy that affects the young in the absence of underlying liver disease. Despite reported small review series, the literature lacks large retrospective studies that may help in understanding this disease.
Related JoVE Video
Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor.
J Gastrointest Cancer
PUBLISHED: 12-13-2011
Show Abstract
Hide Abstract
Secondary malignancies and chronic end-organ sequelae are significant and steadily rising consequences of cancer therapy. The workup and management of a carcinoma of unknown primary must consider the patients clinical presentation, radiologic and pathologic findings, and comorbidities.
Related JoVE Video
Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cancer
PUBLISHED: 06-16-2010
Show Abstract
Hide Abstract
Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKI) in patients with nonsmall cell lung cancer (NSCLC).
Related JoVE Video
A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.
Gastrointest Cancer Res
Show Abstract
Hide Abstract
Flavopiridol, a Cdk inhibitor, potentiates irinotecan-induced apoptosis. In a phase I trial of sequential irinotecan and flavopiridol, 2 patients with advanced hepatocellular carcinoma (HCC) had stable disease (SD) for ?14 months. We thus studied the sequential combination of irinotecan and flavopiridol in patients with HCC.
Related JoVE Video
Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases.
Breast J
Show Abstract
Hide Abstract
Hepatic failure from breast cancer liver metastases (BCLM) is a major cause of morbidity and mortality. We reviewed the treatment histories and outcomes of nine patients with heavily treated BCLM, who received hepatic arterial infusion (HAI) of floxuridine (FUDR)/dexamethasone (Dex) and systemic chemotherapy at our institution. Patients received a median of five (range 1-15) HAI treatments. There were seven (78%) objective responses. Four patients had grade 3 elevations in liver enzymes attributable to HAI. There were no treatment-related deaths. Median hepatic and extrahepatic time to progression on HAI were both 6 months. Median survival after starting HAI was 17 months (range 1-115). Median overall survival from the original breast cancer diagnosis was 110 months (range 52-248). One patient is alive with stable disease on systemic therapy alone. HAI and systemic chemotherapy is feasible and can benefit selected patients with BCLM, who have progressed on prior therapies. Patients require close monitoring for treatment-limiting toxicities.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.